Effects of raloxifene hydrochloride on endometrial cancer cells in vitro

Gynecologic Oncology

Volumn 93, Issue 3, 2004, Pages 642-646

  Hibner, Michael ^a,b   Magrina, Javier F ^b   Lefler, Scott R ^b   Cornella, Jeffrey L ^b   Pizarro, Antonio R ^b   Loftus, Joseph C ^b  

^a MARICOPA MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Endometrial neoplasms; Estradiol; Estrogen receptors; Raloxifene

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RALOXIFENE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG PURIFICATION; ENDOMETRIUM CARCINOMA; GROWTH RATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; CELL DIVISION; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 2942685561     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.007     Document Type: Article

References (31)

1. American cancer society publication - cancer facts and figures 2003, pp. 22.
2. Gray L.A. Sr., Christopherson W.M., Hoover R.N. Estrogens and endometrial carcinoma. Obstet. Gynecol. 49:1977;385-389
3. Smith D.C., Prentice R., Thompson D.J., Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 293:1975;1164-1167
4. Mariani A., Webb M.J., Keeney G.L., Aletti G., Podratz K.C. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol. Oncol. 86:2002;38-44. [doi:10.1006/gyno.2002.6713]
5. Creasman W.T., Soper J.T., McCarty K.S. Jr., McCarty K.S. Sr., Hinshaw W., Clarke-Pearson D.L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am. J. Obstet. Gynecol. 151:1985;922-932
6. Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. Gynecologic Oncology Group Study High-dose megestrol acetate in advanced or recurrent endometrial carcinoma. J. Clin. Oncol. 14:1996;357-361
7. Clark B.F. The effects of oestrogen and progesterone on uterine cell division and epithelial morphology in spayed, adrenalectomized rats. J. Endocrinol. 50:1971;527-528
8. Tachi C., Tachi S., Lindner H.R. Modification by progesterone of oestradiol-induced cell proliferation, RNA synthesis and oestradiol distribution in the rat uterus. J. Reprod. Fertil. 31:1972;59-76
9. Speroff L., Glass R.H., Kase N.G. Clinical gynecologic endocrinology and infertility. Sixth ed. 1999;47-48 Lippincott Williams & Wilkins, Philadelphia
10. Meldrum D.R., Davidson B.J., Tataryn I.V., Judd H.L. Changes in circulating steroids with aging in postmenopausal women. Obstet. Gynecol. 57:1981;624-628
11. Longcope C., Jaffee W., Griffing G. Production rates of androgens and oestrogens in post-menopausal women. Maturitas. 3:1981;215-223
12. Kirschner M.A., Samojlik E., Drejka M., Szmal E., Schneider G., Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J. Clin. Endocrinol. Metab. 70:1990;473-479
13. Webb P., Lopez G.N., Greene G.L., Baxter J.D., Kushner P.J. The limits of the cellular capacity to mediate an estrogen response. Mol. Endocrinol. 6:1992;157-167
14. Clark J.H., Hsueh A.J., Peck E.J. Jr. Regulation of estrogen receptor replenishment by progesterone. Ann. N. Y. Acad. Sci. 286:1977;161-179
15. Richart R.M., Ferenczy A. Endometrial morphologic response to hormonal environment. Gynecol. Oncol. 2:1974;180-197
16. Grese T.A., Sluka J.P., Bryant H.U., Cullinan G.J., Glasebrook A.L., Jones C.D., et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. U. S. A. 94:1997;14105-14110
17. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758
18. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:1997;863-870
19. Sexton M.J., Gherman R.B. Selective estrogen receptor modulators: the ideal estrogen replacement? Prim. Care Update Obstet. Gynecol. 8:2001;25-30
20. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 282:1999;637-645. [published erratum appears in JAMA 282 (1999) 2124]
21. EVISTA®: raloxifene hydrochloride 60 mg tablets. Retrieved July 1, 2003, from the World Wide Web: http://pi.lilly.com/us/evista-pi.pdf.
22. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:1996;905-912
23. Cano A., Hermenegildo C. The endometrial effects of SERMs. Hum. Reprod. Update. 6:2000;244-254
24. Goldstein S.R., Scheele W.H., Rajagopalan S.K., Wilkie J.L., Walsh B.W., Parsons A.K. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet. Gynecol. 95:2000;95-103. [doi:10.1016/S0029-7844(99)00502-5]
25. Gradishar W., Glusman J., Lu Y., Vogel C., Cohen F.J., Sledge G.W. Jr. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer. 88:2000;2047-2053
26. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., Draper M.W. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 177:1997;1458-1464
27. Jones C.D., Jevnikar M.G., Pike A.J., Peters M.K., Black L.J., Thompson A.R., et al. Antiestrogens: 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4- hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl) ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27:1984;1057-1066
28. Lessey B.A., Ilesanmi A.O., Castelbaum A.J., Yuan L., Somkuti S.G., Chwalisz K., et al. Characterization of the functional progesterone receptor in an endometrial adenocarcinoma cell line (Ishikawa): progesterone-induced expression of the alpha1 integrin. J. Steroid Biochem. Mol. Biol. 59:1996;31-39. [doi: 10.1016/S0960-0760(96)00103-3]
29. Cell Titer 96® AQueous One solution cell proliferation assay. Technical Bulletin. vol. 245:1999;Promega Corporation, Madison, WI
30. Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2:2000;335-344. [doi: 10.1186/bcr78]
31. Goldstein S.R. Update on raloxifene to prevent endometrial-breast cancer. Eur. J. Cancer. 36(Suppl. 4):2000;S54-S56. [doi: 10.1016/S09-59-8049(00)00227- 6]